Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.40 USD
−48.82 M USD
81.00 K USD
30.40 M
About Actinium Pharmaceuticals, Inc. (Delaware)
Sector
CEO
Sandesh Seth
Headquarters
New York
Website
Founded
2000
FIGI
BBG000RQZ245
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
soonActinium is the real deal in curing cancer without the need to attack healthy cells. But this company had been manipulated for quite some times now. I think this will be the beginning of a major push up real real soon.
ATNM Technical Analysis 🧙Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cel
ATNM to push towards 12.95!Hi! I'm liking these higher lows in ATNM! Taking a long at 12.12 with a target of 12.95!
$ATNM Actinium Pharmaceuticals, Inc. Revised Targets Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was fou
$atnmGet in at around $.50, ride hype up to $1+. Has a connection to NAK, another mining stock that has just did well in the sector.
$ATNM Actinium Pharmaceuticals, Inc Bullish SignalsActinium Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was fou
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ATNM is 1.22 USD — it has decreased by −1.61% in the past 24 hours. Watch Actinium Pharmaceuticals, Inc. (Delaware) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Actinium Pharmaceuticals, Inc. (Delaware) stocks are traded under the ticker ATNM.
ATNM stock has fallen by −3.94% compared to the previous week, the month change is a −17.01% fall, over the last year Actinium Pharmaceuticals, Inc. (Delaware) has showed a −74.85% decrease.
We've gathered analysts' opinions on Actinium Pharmaceuticals, Inc. (Delaware) future price: according to them, ATNM price has a max estimate of 9.00 USD and a min estimate of 2.00 USD. Watch ATNM chart and read a more detailed Actinium Pharmaceuticals, Inc. (Delaware) stock forecast: see what analysts think of Actinium Pharmaceuticals, Inc. (Delaware) and suggest that you do with its stocks.
ATNM reached its all-time high on Apr 3, 2014 with the price of 450.00 USD, and its all-time low was 1.10 USD and was reached on Dec 19, 2024. View more price dynamics on ATNM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ATNM stock is 7.83% volatile and has beta coefficient of 2.65. Track Actinium Pharmaceuticals, Inc. (Delaware) stock price on the chart and check out the list of the most volatile stocks — is Actinium Pharmaceuticals, Inc. (Delaware) there?
Today Actinium Pharmaceuticals, Inc. (Delaware) has the market capitalization of 38.06 M, it has increased by 1.64% over the last week.
Yes, you can track Actinium Pharmaceuticals, Inc. (Delaware) financials in yearly and quarterly reports right on TradingView.
Actinium Pharmaceuticals, Inc. (Delaware) is going to release the next earnings report on Mar 14, 2025. Keep track of upcoming events with our Earnings Calendar.
ATNM earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.39 USD resulting in a 3.90% surprise. The estimated earnings for the next quarter are −0.37 USD per share. See more details about Actinium Pharmaceuticals, Inc. (Delaware) earnings.
Actinium Pharmaceuticals, Inc. (Delaware) revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ATNM net income for the last quarter is −11.57 M USD, while the quarter before that showed −11.35 M USD of net income which accounts for −1.89% change. Track more Actinium Pharmaceuticals, Inc. (Delaware) financial stats to get the full picture.
No, ATNM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 49.00 employees. See our rating of the largest employees — is Actinium Pharmaceuticals, Inc. (Delaware) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Actinium Pharmaceuticals, Inc. (Delaware) EBITDA is −44.15 M USD, and current EBITDA margin is −63.12 K%. See more stats in Actinium Pharmaceuticals, Inc. (Delaware) financial statements.
Like other stocks, ATNM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Actinium Pharmaceuticals, Inc. (Delaware) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Actinium Pharmaceuticals, Inc. (Delaware) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Actinium Pharmaceuticals, Inc. (Delaware) stock shows the sell signal. See more of Actinium Pharmaceuticals, Inc. (Delaware) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.